Before revision:   These results support studying \alpha_1-AR antagonists for preventing ARDS and reducing mortality in pneumonia and acute respiratory distress, as well as highlight the need for prospective trials of \alpha_1-AR antagonists to assess their efficacy in preventing cytokine storm syndrome and death in COVID-19.
After revision:  Beta-adrenergic receptor antagonists had no significant effects. These results support studying \alpha_1-AR antagonists for preventing ARDS and reducing mortality in pneumonia and acute respiratory distress, as well as highlight the need for prospective trials of \alpha_1-AR antagonists to assess their efficacy in preventing cytokine storm syndrome and death in COVID-19.